WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H522523
CAS#: 300353-13-3
Description: Ro 28-1675 is a potent allosteric GK activator with a SC1.5 value of 0.24± 0.0019 uM. Ro 28-1675 reduced fasting and postprandial glucose levels following an OGTT, was well tolerated, and displayed no adverse effects related to drug administration other than hypoglycemia at the maximum dose (400 mg).
Hodoodo Cat#: H522523
Name: RO 28-1675
CAS#: 300353-13-3
Chemical Formula: C18H22N2O3S2
Exact Mass: 378.11
Molecular Weight: 378.510
Elemental Analysis: C, 57.12; H, 5.86; N, 7.40; O, 12.68; S, 16.94
Synonym: RO28-1675; RO-28-1675; RO 28-1675; RO028-1675; RO-028-1675; RO 028-1675; RO281675; RO 281675; RO-281675; Ro 0281675; Ro-0281675; Ro0281675.
IUPAC/Chemical Name: (2R)-3-Cyclopentyl-2-[4-(methanesulfonyl)phenyl]-N-(thiazol-2-yl)propionamide
InChi Key: NEQSWPCDHDQINX-MRXNPFEDSA-N
InChi Code: InChI=1S/C18H22N2O3S2/c1-25(22,23)15-8-6-14(7-9-15)16(12-13-4-2-3-5-13)17(21)20-18-19-10-11-24-18/h6-11,13,16H,2-5,12H2,1H3,(H,19,20,21)/t16-/m1/s1
SMILES Code: O=C(NC1=NC=CS1)[C@@H](C2=CC=C(S(=O)(C)=O)C=C2)CC3CCCC3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 378.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Roma LP, Duprez J, Jonas JC. Glucokinase activation is beneficial or toxic to cultured rat pancreatic islets depending on the prevailing glucose concentration. Am J Physiol Endocrinol Metab. 2015 Oct 1;309(7):E632-9. doi: 10.1152/ajpendo.00154.2015. Epub 2015 Aug 11. PubMed PMID: 26264555.
2: Al-aryahi S, Kamato D, Getachew R, Zheng W, Potocnik SJ, Cohen N, Guidone D, Osman N, Little PJ. Atherogenic, fibrotic and glucose utilising actions of glucokinase activators on vascular endothelium and smooth muscle. Cardiovasc Diabetol. 2014 Apr 15;13:80. doi: 10.1186/1475-2840-13-80. PubMed PMID: 24731772; PubMed Central PMCID: PMC4016772.
3: Assefa Z, Lavens A, Steyaert C, Stangé G, Martens GA, Ling Z, Hellemans K, Pipeleers D. Glucose regulates rat beta cell number through age-dependent effects on beta cell survival and proliferation. PLoS One. 2014 Jan 9;9(1):e85174. doi: 10.1371/journal.pone.0085174. eCollection 2014. PubMed PMID: 24416358; PubMed Central PMCID: PMC3887027.
4: Huo LC, Zhang YL, Lei L, Liu SN, Shen ZF, Wang YL, Song HR, Feng ZQ. [Salicylic acid derivatives as simplified and novel GK small molecule activators]. Yao Xue Xue Bao. 2013 Apr;48(4):514-20. Chinese. PubMed PMID: 23833938.
5: Pal M. Medicinal chemistry approaches for glucokinase activation to treat type 2 diabetes. Curr Med Chem. 2009;16(29):3858-74. Review. PubMed PMID: 19747136.
6: Wu CF, Xu Y, Tao Y, Yang JY. Establishment of hypoglycemic agent screening method based on human glucokinase. Biomed Environ Sci. 2009 Feb;22(1):62-9. doi: 10.1016/S0895-3988(09)60024-6. PubMed PMID: 19462690.
7: Kumari V, Li C. Comparative docking assessment of glucokinase interactions with its allosteric activators. Curr Chem Genomics. 2008 Dec 30;2:76-89. doi: 10.2174/1875397300802010076. PubMed PMID: 20161845; PubMed Central PMCID: PMC2803441.
8: Li YQ, Feng ZQ, Song HR, Guo YS, Guo ZR. [Advances in the study of glucokinase and small molecule glucokinase activators]. Yao Xue Xue Bao. 2006 May;41(5):390-4. Review. Chinese. PubMed PMID: 16848312.
9: Sarabu R. Anglo-Swedish Medicinal Chemistry - second symposium. IDrugs. 2005 May;8(5):384-6. PubMed PMID: 15883916.
10: McKerrecher D, Allen JV, Bowker SS, Boyd S, Caulkett PW, Currie GS, Davies CD, Fenwick ML, Gaskin H, Grange E, Hargreaves RB, Hayter BR, James R, Johnson KM, Johnstone C, Jones CD, Lackie S, Rayner JW, Walker RP. Discovery, synthesis and biological evaluation of novel glucokinase activators. Bioorg Med Chem Lett. 2005 Apr 15;15(8):2103-6. PubMed PMID: 15808477.
11: Al-Hasani H, Tschöp MH, Cushman SW. Two birds with one stone: novel glucokinase activator stimulates glucose-induced pancreatic insulin secretion and augments hepatic glucose metabolism. Mol Interv. 2003 Oct;3(7):367-70. Review. PubMed PMID: 14993457.
12: Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, Guertin KR, Hilliard DW, Kester RF, Mahaney PE, Marcus L, Qi L, Spence CL, Tengi J, Magnuson MA, Chu CA, Dvorozniak MT, Matschinsky FM, Grippo JF. Allosteric activators of glucokinase: potential role in diabetes therapy. Science. 2003 Jul 18;301(5631):370-3. PubMed PMID: 12869762.